Axogen Completes $200 Million BioCircuit Acquisition
Axogen closed its $200 million cash purchase of BioCircuit on 1 October, adding NerveTape, an FDA-cleared sutureless nerve repair device, to its portfolio.
Axogen closed its $200 million cash purchase of BioCircuit on 1 October, adding NerveTape, an FDA-cleared sutureless nerve repair device, to its portfolio.